Hydrochloric Acid

Hydrochloric Acid

SCHEMBL1669691

CN[C@@H](C)C(N)=O.Cl

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2227950 1.00
Hydrochloric Acid SCHEMBL15414358 1.00
SCHEMBL4447524 0.97
SCHEMBL821091 0.97
SCHEMBL300789 0.97
Trifluoroacetic Acid SCHEMBL16718050 0.81 CHIT1 (0.31)
Trifluoroacetic Acid SCHEMBL30388501 0.81 CHIT1 (0.31)
Valine SCHEMBL2227890 0.79 SLC7A5 (0.62)
SCHEMBL30675661 0.78
Beta-Alanine SCHEMBL3195784 0.78 GABRP (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104470905-B The miscellaneous azepine * assimilation compounds of substitution 霍夫曼-拉罗奇有限公司 2017-09-12 CN claimed
EP-0136720-A2 Enkephalin analogs G.D. Searle & Co. (US) 1985-04-10 EP claimed
EP-3897972-B1 LIGAND LINKER SUBSTRATE CHRETO APS (DK) 2024-10-02 EP disclosed
EP-4134157-B1 USE OF LIGAND LINKER SUBSTRATE FOR PURIFICATION CHRETO APS (DK) 2024-10-02 EP disclosed
EP-4134158-B1 LIGAND LINKER SUBSTRATE SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2024-05-15 EP disclosed
EP-4134157-A1 USE OF LIGAND LINKER SUBSTRATE FOR PURIFICATION CHRETO ApS (DK) 2023-02-15 EP disclosed
EP-4134158-A1 LIGAND LINKER SUBSTRATE 3M Innovative Properties Company (US) 2023-02-15 EP disclosed
CN-114452961-A Use of ligand functionalized substrates for purification of target biomolecules 科雷托公司 2022-05-10 CN disclosed
CN-114456192-A Compounds, polymers, ligand functionalized substrates and uses 3M创新产权公司 2022-05-10 CN disclosed
US-20220048010-A1 Ligand linker substrate 3M INNOVATIVE PROPERTIES COMPANY 2022-02-17 US disclosed
CN-104470905-B The miscellaneous azepine * assimilation compounds of substitution 霍夫曼-拉罗奇有限公司 2017-09-12 CN disclosed
WO-2011045259-A1 AMINOPROPENOATES AS FUNGICIDES BAYER CROPSCIENCE AG (DE) 2011-04-21 WO disclosed
US-7718815-B2 Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders NEWRON PHARMACEUTICALS S.P.A. (IT) 2010-05-18 US disclosed
US-20080132567-A1 Alpha-Aminoamide Derivatives Useful in the Treatment of Lower Urinary Tract Disorders NEWRON PHARMACUETICALS S.P.A (IT) 2008-06-05 US disclosed
EP-1597261-A1 SUBSTITUTED AMINO HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2005-11-23 EP disclosed
WO-2005070405-A1 ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF LOWER URINARY TRACT DISORDERS NEWRON PHARMACEUTICALS S.P.A. (IT) 2005-08-04 WO disclosed
EP-1557166-A1 Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders Newron Pharmaceuticals S.p.A. (IT) 2005-07-27 EP disclosed
WO-2004074290-A1 SUBSTITUTED AMINO HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2004-09-02 WO disclosed
EP-0136720-B1 ENKEPHALIN ANALOGS G.D. Searle & Co. (US) 1989-09-20 EP disclosed
EP-0136720-A2 Enkephalin analogs G.D. Searle & Co. (US) 1985-04-10 EP disclosed